Palo Alto, CA, United States of America

J Paul Woodard

This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Immune-Onc Therapeutics, Inc.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: J Paul Woodard. Retrieved from https://idiyas.com/inventor/j-paul-woodard

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 11.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: J Paul Woodard: Innovator in Antibody Development

Introduction

J Paul Woodard is a notable inventor based in Palo Alto, CA. He has made significant contributions to the field of biotechnology, particularly in the development of novel antibodies. His work is instrumental in advancing therapeutic options for various diseases.

Latest Patents

J Paul Woodard holds a patent for "Novel Anti-LILRB4 Antibodies and Derivative Products." This patent represents his innovative approach to targeting specific proteins that play a role in immune response. The patent is a testament to his expertise and dedication to improving healthcare solutions. He has 1 patent to his name.

Career Highlights

Woodard is currently associated with Immune-Onc Therapeutics, Inc., where he continues to push the boundaries of research and development in immunotherapy. His role at the company allows him to collaborate with other experts in the field and contribute to groundbreaking projects.

Collaborations

He works alongside talented colleagues, including X Charlene Liao and Caroline Bonnans. Their combined efforts enhance the research environment and foster innovation within the company.

Conclusion

J Paul Woodard's contributions to antibody development exemplify the impact of dedicated inventors in the biotechnology sector. His work not only advances scientific knowledge but also holds promise for future therapeutic applications.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…